Print  |  Close

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma


Active: Yes
Cancer Type: Kidney Cancer
Unknown Primary
NCT ID: NCT07011719
Trial Phases: Phase III Protocol IDs: PEAK-1 (primary)
NCI-2025-05062
2024-515023-11-00
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Arcus Biosciences, Inc.
NCI Full Details: http://clinicaltrials.gov/show/NCT07011719

Summary

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan
versus placebo when each is given in combination with cabozantinib in adult patients with
confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced
progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Treatment Sites in Georgia

Piedmont Cancer Institute - Atlanta
1800 Howell Mill Road
Suite 800
Atlanta, GA 30318
678-298-3238
www.piedmontcancerinstitute.com



Piedmont Cancer Institute - Fayetteville
1267 Highway 54 West
Suite 4200
Fayetteville, GA 30214
678-298-3238
www.piedmontcancerinstitute.com



Piedmont Cancer Institute – Locust Grove
4877 Bill Gardner Pkwy
Locust Grove, GA 30248




Piedmont Cancer Institute - Newnan
775 Poplar Road
Suite 310
Newnan, GA 30265
678-298-3238
www.piedmontcancerinstitute.com



Piedmont Cancer Institute – Sandy Springs
Piedmont Cancer Institute – Sandy Springs
755 Mount Vernon Hwy
Suite 320
Atlanta, GA 30328




Piedmont Cancer Institute - Stockbridge
290 Country Club Drive
Suite 100
Stockbridge, GA 30281
678-298-3238
www.piedmontcancerinstitute.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.